Stock AnalizNovartis AG (NVS) earnings for the quarter ended September 2026: EPS beats estimates
Novartis AG reported results for the quarter ended September 2026 on October 27, 2026. Adjusted earnings per share came in at $2.46 against the analysts’ average forecast of $2.24, a beat of 9.7%.
Revenue for the quarter was $15.03 billion, up 4.7% from $14.36 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 2.0% on the first trading day after the report.
The last four quarters
Novartis AG has beaten the analysts’ EPS forecast in 1 of the last 1 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $2.46 | $2.24 | +9.7% | +5% | +2.0% |
What comes next
Analysts expect EPS of $2.23 for the next quarter on average and $9.07 for the fiscal year ending December 31, 2026.
The average analyst price target is $157.10, 2% below the current price of $160.50.
Valuation and score
Novartis AG scores 2.0 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 30.7, and its intrinsic value under moderate assumptions is about 9% below the current market value. Full Novartis AG analysis with 10 years of financials
Frequently asked questions
What was Novartis AG’s EPS for the quarter ended September 2026?
$2.46 adjusted per share, against an analyst consensus of $2.24.
How much revenue did Novartis AG report?
$15.03 billion, up 4.7% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.